menu
    • menu
    [{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Genson Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Funding","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Genson Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Genson Capital"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Financing","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec"}]

    Find Clinical Drug Pipeline Developments & Deals by Neurenati Therapeutics

    Menu

    Neurenati Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neurenati Therapeutics

                            Canada arrow
                            IMCAS Asia
                            Not Confirmed

                            Neurenati Therapeutics

                            Canada arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan & Rare Pediatric Status to Neurenati’s NEU-001 for Hirschsprung

                            Details : NEU-001 is a first-in-class, once-in-a-lifetime treatment administered intrarectally, which is being evaluated to treat Hirschsprung's disease.

                            Product Name : NEU-001

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 04, 2025

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neurenati Therapeutics

                            Canada arrow
                            IMCAS Asia
                            Not Confirmed

                            Neurenati Therapeutics

                            Canada arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Investissement Québec

                            Deal Size : $2.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Neurenati Concludes $1.7 Million Seed Financing with Support from Impulsion PME

                            Details : The proceeds will be used to effectively advance NEU-001 toward clinical trials. NEU-001 is a proposed first-in-class therapy to treat Hirschsprung's disease, a rare gastrointestinal disease.

                            Product Name : NEU-001

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            April 18, 2024

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Investissement Québec

                            Deal Size : $2.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neurenati Therapeutics

                            Canada arrow
                            IMCAS Asia
                            Not Confirmed

                            Neurenati Therapeutics

                            Canada arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Genson Capital

                            Deal Size : $1.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Neurenati Completes $1.2 Million Seed Financing for NEU-001 in Hirschsprung Disease

                            Details : The funding will accelerate the development of Neurenati's NEU-001, which is being evaluated in the preclinical studies for the treatment of Hirschsprung’s disease.

                            Product Name : NEU-001

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 29, 2024

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Genson Capital

                            Deal Size : $1.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth